May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Effectiveness of 1–hydroxyvitamin D2 (1–OH–D2) in Inhibiting Tumor Growth in the Tyr–Tag Transgenic Pigmented Ocular Tumor Model
Author Affiliations & Notes
  • A. Kumar
    Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI
  • D.M. Albert
    Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI
  • S. Darjatmoko
    Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI
  • S. Strugnell
    Bonecare International, Middleton, WI
  • C.M. Damico
    Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI
  • Footnotes
    Commercial Relationships  A. Kumar, None; D.M. Albert, None; S. Darjatmoko, None; S. Strugnell, Bonecare International E; C.M. Damico, None.
  • Footnotes
    Support  NIH grant EYO1917 and an unrestricted award from Research to Prevent Blindness, New York, NY
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3578. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Kumar, D.M. Albert, S. Darjatmoko, S. Strugnell, C.M. Damico; Effectiveness of 1–hydroxyvitamin D2 (1–OH–D2) in Inhibiting Tumor Growth in the Tyr–Tag Transgenic Pigmented Ocular Tumor Model . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3578.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To study the effectiveness of the vitamin D analog 1α–hydroxyvitamin D2 (1α–OH–D2) in inhibiting ocular tumor growth in Tyr–Tag transgenic mice. These animals develop pigmented intraocular tumors primarily from the retinal pigment epithelium which closely resemble the histology and growth pattern of human choroidal melanoma. Methods: A total of 73 Tyr–Tag transgenic mice between six and seven weeks old were randomly assigned by sex and litter to three treatment groups receiving 0.05 µg, 0.1 µg, or 0.2 µg per day of 1α–OH–D2 and a control group receiving vehicle. The drug was administered by oral gavage five times a week for five weeks. The animals were then euthanized and their eyes were enucleated and processed histologically. Three serial sections from each eye were examined microscopically and the mean tumor area measured using Optimas software version 6.5 (Media cybernetics, LP, Silver Spring, MD). Toxicity was assessed on the basis of mortality, weight loss, serum calcium levels, and kidney calcification. Results: The mean tumor size in the 0.1 and 0.2 µg per day treatment groups was smaller than in the controls (p < 0.001). No significant difference was seen between the 0.05 µg per day treatment group and the controls (p = 0.63). Survival in the 0.1 and 0.2 µg treated groups was lower than the controls (95% versus 85.7% versus 74.7%; p < 0.01). Conclusions: In the Tyr–Tag mouse 1α–OH–D2 inhibits pigmented ocular tumor growth at moderate drug levels with relatively low mortality.

Keywords: melanoma • tumors • transgenics/knock–outs 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×